This segment focuses on the research, development, and clinical trials of novel cancer therapies, primarily leveraging PLK1 inhibition. Cardiff Oncology's lead drug candidate, onvansertib, is an oral selective Polo-like Kinase 1 (PLK1) inhibitor being evaluated in multiple clinical trials for various cancers, including metastatic colorectal cancer (mCRC), and metastatic castration-resistant prostate cancer (mCRPC). Research and development activities include preclinical studies, Phase 1/2 and Phase 2 clinical trials, and biomarker analysis to identify patient populations most likely to benefit from treatment. The company utilizes advanced technologies and methodologies in drug discovery, including molecular biology and clinical research. The primary therapeutic area is oncology, with a focus on solid tumors and leukemias. The goal is to improve patient outcomes by providing targeted therapies with the potential for improved efficacy and reduced side effects. Cardiff Oncology aims to gain a competitive advantage through its focus on precision medicine and biomarker-driven drug development. Future opportunities include expanding the clinical trial portfolio and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial protocols. Partnerships with pharmaceutical companies, such as Pfizer, are key to advancing clinical programs.